PERTH, AUSTRALIA: MGC Pharmaceuticals has entered into an exclusive commercial wholesale supply agreement with Polish NGO Cannabis House Association (Stowarzyszenie Cannabis House) and the Forensic Laboratory of the Faculty of Law and Administration of the University of Łódź in Poland, a key EU market.
The Agreement sets out the terms under which MGC Pharma will supply its cannabinoid medicine products, and scientific support, to support a large-scale commercial research study aimed at collecting data on medicinal cannabis users and products in Poland.
The Project will supply cannabis products and collect important study participant data on access to registered and regulated cannabis products to users in Poland through 15 pharmacies immediately, and will expand to 50 pharmacies within nine months.
MGC Pharma will be the exclusive supplier of its phytocannabinoid products, which will be based on CannEpil, CogniCann, and the Mercury Pharma line, via a commercial wholesale supply agreement into pharmacies and authorised dispensaries, and arrange supply of other cannabis products as required for the Project. There is no minimum order volume under the agreement.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “We have continued to build momentum this year by adding Poland to the list of countries where our phytocannabinoid-derived medicines are available, which follows our entry into Ireland in December after receiving formal approval for the sale of CannEpil.
“The combination of a truly distinctive research project such as this one, run by a highly regarded university in the University of Łódź, with the market potential of Poland and government support, creates a unique opportunity for MGC Pharma to access to a large EU market immediately, drive revenues, and generate significant patient data. Additionally, the prospect of researching easier access to regulated products is one that appeals to MGC Pharma’s scientific board, creating data that will hopefully support this agenda on a global level.”
PhD Piotr Grzegorczyk, Chair of Scientific Council of Cannabis House Association, Adjunct . at Faculty of Law and Administration, University of Lodz, said: “We are very pleased to partner with a high quality partner in MGC Pharma, which helps us assure that patients and users in Poland will receive the highest quality cannabis products.
“Current research shows that today’s drug policy doesn’t meet its goals and our project should help to evoke its change and to actually minimise harmful effects of cannabis usage in Poland, through conditional permission for possession and house-usage and through education of society. I trust this project will significantly improve quality of life for patients and users of cannabis. This cooperation between the University, MGC and the Association is a unique opportunity for the many years of experience acquired by MGC to assist in the development of Polish science.”